Coronary heart disease secondary prevention
Coronary heart disease Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Coronary heart disease secondary prevention On the Web |
American Roentgen Ray Society Images of Coronary heart disease secondary prevention |
Risk calculators and risk factors for Coronary heart disease secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Lipid Management
Secondary prevention
- Start dietary therapy (<7% of total calories as saturated fat and <200 mg/d cholesterol)
- Add plant stanol/sterols (2 gm/day) and viscous fiber (>10 mg/day)
- Promote daily physical activity and weight management.
- Omega-3 fatty acids in fish or 1 g/day
- Omega-3 fatty acids in capsule form.
Physical Activity Recommendations
- Encourage 30 to 60 minutes of moderate intensity aerobic activity such as brisk walking, on most, preferably all, days of the week.
- Advise medically supervised programs for high-risk patients (e.g. recent acute coronary syndrome or revascularization, heart failure)
Weight Management
- Goal: BMI 18.5 to 24.9 kg/m2
- Waist Circumference:
- Men: < 40 inches
- Women: < 35 inches
- If waist circumference >35 inches in women and >40 inches in men initiate lifestyle changes and consider treatment strategies for metabolic syndrome as indicated.
- The initial goal of weight loss therapy should be to reduce body weight by approximately 5-10 percent from baseline.
ACE Inhibition
- Use in all patients with LVEF < 40%, and those with diabetes or chronic kidney disease indefinitely, unless contraindicated
- Consider for all other patients
Angiotensin Receptor Blockade
- Use in patients who are intolerant of ACE inhibitors with heart failure or post MI with LVEF less than or equal to 40%.
- Consider in other patients who are ACE inhibitor intolerant.
Diabetes Mellitus
- Lifestyle and pharmacotherapy to achieve HbA1C <7% may be considered.
- Less stringent goal for may be considered (severe hypoglycemia, limited life expectancy, extensive comorbidities)
Anti-platelet therapy
A meta-analysis of randomized controlled trials by the international Cochrane Collaboration found "that the use of clopidogrel plus aspirin is associated with a reduction in the risk of cardiovascular events compared with aspirin alone in patients with acute non-ST coronary syndrome. In patients at high risk of cardiovascular disease but not presenting acutely, there is only weak evidence of benefit and hazards of treatment almost match any benefit obtained.".[1]
References
- ↑ Keller T, Squizzato A, Middeldorp S (2007). "Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease". Cochrane database of systematic reviews (Online) (3): CD005158. doi:10.1002/14651858.CD005158.pub2. PMID 17636787.